Fanconi anemia phenotypic and transplant outcomes' associations in Iranian patients
Abstract Objectives Fanconi anemia (FA) is a rare, heterogeneous, inherited disorder. Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only therapeutic option to restore normal hematopoiesis. This study reports the outcomes of FA‐HSCT patients and identifies factors, includin...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.1180 |
| _version_ | 1797839736505630720 |
|---|---|
| author | Faezeh Ansari Maryam Behfar Parisa Naji Zahra Darvish Tahereh Rostami Rashin Mohseni Kamran Alimoghaddam Pouria Salajegheh Batool Ahadi Mahta Mardani Amir Ali Hamidieh |
| author_facet | Faezeh Ansari Maryam Behfar Parisa Naji Zahra Darvish Tahereh Rostami Rashin Mohseni Kamran Alimoghaddam Pouria Salajegheh Batool Ahadi Mahta Mardani Amir Ali Hamidieh |
| author_sort | Faezeh Ansari |
| collection | DOAJ |
| description | Abstract Objectives Fanconi anemia (FA) is a rare, heterogeneous, inherited disorder. Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only therapeutic option to restore normal hematopoiesis. This study reports the outcomes of FA‐HSCT patients and identifies factors, including clinical phenotype. Our team examined more than 95% of Iranian FA patients during the last decade. Study Design One hundred and six FA patients (age range: 2–41) who underwent HSCT from March 2007 to February 2018 were enrolled. Clinical characteristics of genetic disease, pre‐HSCT findings, HSCT indication, and long‐term follow‐up evaluated and recorded. Data were analyzed using SPSS 19.0. Results The mean follow‐up period for survivors was 36 months (range, 1–101). The 3‐year overall survival (OS) and disease‐free survival were 72.2% and 71.2%, respectively. The 3‐year OS rate for patients with limited and extensive malformations was 78.8% and 56.6%, respectively (p = 0.025). Acute graft versus host disease incidence was 60.52% for patients with limited malformations versus 70% for patients with extensive ones (p = 0.49). Chronic graft versus host disease incidence for these two groups was 9.21% and 10%, respectively (p = 0.91). Conclusions OS was not associated with each of the malformations singly; however, it was lower in the extensive group. The younger age of patients at the HSCT time leads to a higher OS. The differences in FA patients' outcomes and the various genotypes were probably related. These data provide a powerful tool for further studies on genotype–phenotype association with HSCT results. |
| first_indexed | 2024-04-09T16:02:58Z |
| format | Article |
| id | doaj.art-8255fbed849e434eb853e95d2200e104 |
| institution | Directory Open Access Journal |
| issn | 2398-8835 |
| language | English |
| last_indexed | 2024-04-09T16:02:58Z |
| publishDate | 2023-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Health Science Reports |
| spelling | doaj.art-8255fbed849e434eb853e95d2200e1042023-04-25T08:04:33ZengWileyHealth Science Reports2398-88352023-04-0164n/an/a10.1002/hsr2.1180Fanconi anemia phenotypic and transplant outcomes' associations in Iranian patientsFaezeh Ansari0Maryam Behfar1Parisa Naji2Zahra Darvish3Tahereh Rostami4Rashin Mohseni5Kamran Alimoghaddam6Pouria Salajegheh7Batool Ahadi8Mahta Mardani9Amir Ali Hamidieh10Pediatric Cell and Gene Therapy Research Centre, Gene, Cell & Tissue Research Institute Tehran University of Medical Sciences Tehran IranPediatric Cell and Gene Therapy Research Centre, Gene, Cell & Tissue Research Institute Tehran University of Medical Sciences Tehran IranPediatric Cell and Gene Therapy Research Centre, Gene, Cell & Tissue Research Institute Tehran University of Medical Sciences Tehran IranInstitute for Oncology, Hematology and Cell Therapy, Shariati Hospital Tehran University of Medical Sciences Tehran IranInstitute for Oncology, Hematology and Cell Therapy, Shariati Hospital Tehran University of Medical Sciences Tehran IranPediatric Cell and Gene Therapy Research Centre, Gene, Cell & Tissue Research Institute Tehran University of Medical Sciences Tehran IranHematology‐Oncology and Stem Cell Transplantation Research Center Tehran University of Medical Sciences Tehran IranDepartment of Pediatric, Faculty of Medicine Kerman University of Medical Sciences Kerman IranPediatric Cell and Gene Therapy Research Centre, Gene, Cell & Tissue Research Institute Tehran University of Medical Sciences Tehran IranPediatric Cell and Gene Therapy Research Centre, Gene, Cell & Tissue Research Institute Tehran University of Medical Sciences Tehran IranPediatric Cell and Gene Therapy Research Centre, Gene, Cell & Tissue Research Institute Tehran University of Medical Sciences Tehran IranAbstract Objectives Fanconi anemia (FA) is a rare, heterogeneous, inherited disorder. Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only therapeutic option to restore normal hematopoiesis. This study reports the outcomes of FA‐HSCT patients and identifies factors, including clinical phenotype. Our team examined more than 95% of Iranian FA patients during the last decade. Study Design One hundred and six FA patients (age range: 2–41) who underwent HSCT from March 2007 to February 2018 were enrolled. Clinical characteristics of genetic disease, pre‐HSCT findings, HSCT indication, and long‐term follow‐up evaluated and recorded. Data were analyzed using SPSS 19.0. Results The mean follow‐up period for survivors was 36 months (range, 1–101). The 3‐year overall survival (OS) and disease‐free survival were 72.2% and 71.2%, respectively. The 3‐year OS rate for patients with limited and extensive malformations was 78.8% and 56.6%, respectively (p = 0.025). Acute graft versus host disease incidence was 60.52% for patients with limited malformations versus 70% for patients with extensive ones (p = 0.49). Chronic graft versus host disease incidence for these two groups was 9.21% and 10%, respectively (p = 0.91). Conclusions OS was not associated with each of the malformations singly; however, it was lower in the extensive group. The younger age of patients at the HSCT time leads to a higher OS. The differences in FA patients' outcomes and the various genotypes were probably related. These data provide a powerful tool for further studies on genotype–phenotype association with HSCT results.https://doi.org/10.1002/hsr2.1180congenital abnormalitiesFanconi anemiahematopoietic stem cell transplantationphenotype |
| spellingShingle | Faezeh Ansari Maryam Behfar Parisa Naji Zahra Darvish Tahereh Rostami Rashin Mohseni Kamran Alimoghaddam Pouria Salajegheh Batool Ahadi Mahta Mardani Amir Ali Hamidieh Fanconi anemia phenotypic and transplant outcomes' associations in Iranian patients Health Science Reports congenital abnormalities Fanconi anemia hematopoietic stem cell transplantation phenotype |
| title | Fanconi anemia phenotypic and transplant outcomes' associations in Iranian patients |
| title_full | Fanconi anemia phenotypic and transplant outcomes' associations in Iranian patients |
| title_fullStr | Fanconi anemia phenotypic and transplant outcomes' associations in Iranian patients |
| title_full_unstemmed | Fanconi anemia phenotypic and transplant outcomes' associations in Iranian patients |
| title_short | Fanconi anemia phenotypic and transplant outcomes' associations in Iranian patients |
| title_sort | fanconi anemia phenotypic and transplant outcomes associations in iranian patients |
| topic | congenital abnormalities Fanconi anemia hematopoietic stem cell transplantation phenotype |
| url | https://doi.org/10.1002/hsr2.1180 |
| work_keys_str_mv | AT faezehansari fanconianemiaphenotypicandtransplantoutcomesassociationsiniranianpatients AT maryambehfar fanconianemiaphenotypicandtransplantoutcomesassociationsiniranianpatients AT parisanaji fanconianemiaphenotypicandtransplantoutcomesassociationsiniranianpatients AT zahradarvish fanconianemiaphenotypicandtransplantoutcomesassociationsiniranianpatients AT taherehrostami fanconianemiaphenotypicandtransplantoutcomesassociationsiniranianpatients AT rashinmohseni fanconianemiaphenotypicandtransplantoutcomesassociationsiniranianpatients AT kamranalimoghaddam fanconianemiaphenotypicandtransplantoutcomesassociationsiniranianpatients AT pouriasalajegheh fanconianemiaphenotypicandtransplantoutcomesassociationsiniranianpatients AT batoolahadi fanconianemiaphenotypicandtransplantoutcomesassociationsiniranianpatients AT mahtamardani fanconianemiaphenotypicandtransplantoutcomesassociationsiniranianpatients AT amiralihamidieh fanconianemiaphenotypicandtransplantoutcomesassociationsiniranianpatients |